{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:59:15Z","timestamp":1780991955735,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) is a chronic and complex respiratory disorder associated with airflow limitation and increased inflammatory response of the lungs to harmful particles. The purpose of this original study was to describe the results and profile of the Shahrekord Prospective\u00a0Epidemiological\u00a0Research\u00a0Studies in\u00a0IrAN (PERSIAN) regarding COPD in southwestern Iran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study of asthma and respiratory diseases is a subcohort of the more extensive cohort study, i.e., Shahrekord PERSIAN cohort, a population-based prospective study on people aged 35\u201370\u00a0years in southwestern Iran (n\u2009=\u200910,075). The sample size of the subcohort was 8500 people. Annual follow-ups (person-year) of the cohort were designed to be conducted up to 2036. The instruments to collect data on various exposures were derived from the questionnaires previously developed in extensive multinational studies (occupational exposures, smoking, housing status, and fuel consumption, history of respiratory and chronic diseases, comorbidity, etc.). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the lower limit of normal (LLN) spirometric criteria were used to confirm COPD diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The response rate was 93.85%. The mean age of the participants was 49.48\u2009\u00b1\u20099.32; 47.9% were male, and 52.9% were female; nearly 16% of the population was current smokers; the fuel used by most of the participants for heating the house and cooking was gas. The most common comorbidity among participants was dyslipidemia; 30% of people have three or more comorbidities. According to GOLD and LLN criteria, the Prevalence of COPD was 3.6% and 8.4%, respectively. 4.3% of the participants had a history of chronic lung disease. The group of subjects with COPD had higher mean age, fewer years of schooling, a higher percentage of smokers with a smoking history of 10 or more pack years. 4.6% of patients had a history of chronic lung disease, 17.6% had a history of asthma in childhood, and 5.2% had a family history of respiratory and pulmonary diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Epidemiological research is necessary to create an appropriate framework to fight COPD. This framework requires a better description of men and women at risk of developing COPD and describing people with early-stage illnesses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-021-01469-8","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T10:03:04Z","timestamp":1616666584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Profile and preliminary results of Iranian sub cohort chronic obstructive pulmonary disease (COPD) in Shahrekord PERSIAN cohort in southwest Iran"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-6910","authenticated-orcid":false,"given":"Fatemeh Zeynab","family":"Kiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-2136","authenticated-orcid":false,"given":"Ali","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar Soleymani","family":"Babadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Rouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"4","key":"1469_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","volume":"187","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Hurd SS, Agust\u00ed AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"1469_CR2","first-page":"1046","volume":"46","author":"MA Garcia-Gordillo","year":"2017","unstructured":"Garcia-Gordillo MA, Collado-Mateo D, Olivares PR, Adsuar JC, Merellano-Navarro E. A cross-sectional assessment of health-related quality of life among patients with chronic obstructive pulmonary disease. Iran J Public Health. 2017;46(8):1046.","journal-title":"Iran J Public Health."},{"issue":"3","key":"1469_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1183\/09031936.06.00124605","volume":"28","author":"R Halbert","year":"2006","unstructured":"Halbert R, Natoli J, Gano A, Badamgarav E, Buist AS, Mannino D. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523\u201332.","journal-title":"Eur Respir J"},{"issue":"3","key":"1469_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1183\/09031936.00038309","volume":"36","author":"A Melville","year":"2010","unstructured":"Melville A, Pless-Mulloli T, Afolabi O, Stenton S. COPD prevalence and its association with occupational exposures in a general population. Eur Respir J. 2010;36(3):488\u201393.","journal-title":"Eur Respir J"},{"key":"1469_CR5","doi-asserted-by":"publisher","first-page":"7518287","DOI":"10.1155\/2016\/7518287","volume":"2016","author":"M Doucet","year":"2016","unstructured":"Doucet M, Rochette L, Hamel D. Incidence, prevalence, and mortality trends in chronic obstructive pulmonary disease over 2001 to 2011: a public health point of view of the burden. Can Respir J. 2016;2016:7518287.","journal-title":"Can Respir J."},{"issue":"5","key":"1469_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1155\/2012\/328460","volume":"19","author":"MR Maleki-Yazdi","year":"2012","unstructured":"Maleki-Yazdi MR, Kelly SM, Lam SS, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319\u201324.","journal-title":"Can Respir J"},{"key":"1469_CR7","doi-asserted-by":"crossref","first-page":"8184915","DOI":"10.1155\/2017\/8184915","volume":"2017","author":"T Dang-Tan","year":"2017","unstructured":"Dang-Tan T, Zhang S, Tavares RV, Stutz M, Ismaila AS, Vaillancourt J, et al. The burden of illness related to chronic obstructive pulmonary disease exacerbations in Qu\u00e9bec, Canada. Can Respir J. 2017;2017:8184915.","journal-title":"Can Respir J."},{"issue":"1","key":"1469_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.26719\/emhj.18.014","volume":"25","author":"M Varmaghani","year":"2019","unstructured":"Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019;25(1):47\u201357.","journal-title":"East Mediterr Health J"},{"key":"1469_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/ijpvm.IJPVM_478_18","volume":"11","author":"H Sharifi","year":"2020","unstructured":"Sharifi H, Ghanei M, Jamaati H, Masjedi MR, Aarabi M, Sharifpour A, et al. Burden of obstructive lung disease in Iran: Prevalence and risk factors for COPD in North of Iran. Int J Prev Med. 2020;11:78.","journal-title":"Int J Prev Med"},{"issue":"6","key":"1469_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4103\/0970-2113.168129","volume":"32","author":"H Sharifi","year":"2015","unstructured":"Sharifi H, Masjedi MR, Emami H, Ghanei M, Eslaminejad A, Radmand G, et al. Burden of obstructive lung disease study in Tehran: prevalence and risk factors of chronic obstructive pulmonary disease. Lung India J. 2015;32(6):572.","journal-title":"Lung India J"},{"issue":"7","key":"1469_CR11","first-page":"885","volume":"16","author":"B Amra","year":"2011","unstructured":"Amra B, Golshan M, Fietze I, Penzel T, Welte T. Correlation between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome in a general population in Iran. J Res Med Sci. 2011;16(7):885.","journal-title":"J Res Med Sci"},{"issue":"1","key":"1469_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/lungindia.lungindia_129_18","volume":"36","author":"H Sharifi","year":"2019","unstructured":"Sharifi H, Ghanei M, Jamaati H, Masjedi MR, Aarabi M, Sharifpour A, et al. Burden of obstructive lung disease study in Iran: first report of the prevalence and risk factors of COPD in five provinces. Lung India J. 2019;36(1):14.","journal-title":"Lung India J"},{"issue":"2","key":"1469_CR13","first-page":"93","volume":"15","author":"M Varmaghani","year":"2016","unstructured":"Varmaghani M, Farzadfar F, Sharifi F, Rashidain A, Moin M, Moradi-Lakeh M, et al. prevalence of asthma, COPD, and chronic bronchitis in Iran: A systematic review and meta-analysis. Iran J Allergy Asthma Immunol. 2016;15(2):93.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"1469_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-017-0643-5","volume":"18","author":"A Horner","year":"2017","unstructured":"Horner A, Soriano JB, Puhan MA, Studnicka M, Kaiser B, Vanfleteren LE, et al. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respir Res. 2017;18(1):162.","journal-title":"Respir Res"},{"issue":"1","key":"1469_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12931-015-0198-2","volume":"16","author":"D Jaganath","year":"2015","unstructured":"Jaganath D, Miranda JJ, Gilman RH, Wise RA, Diette GB, Miele CH, et al. prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respir Res. 2015;16(1):40.","journal-title":"Respir Res"},{"issue":"2","key":"1469_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1378\/chest.07-1361","volume":"133","author":"A Caballero","year":"2008","unstructured":"Caballero A, Torres-Duque CA, Jaramillo C, Bol\u00edvar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343\u20139.","journal-title":"Chest"},{"issue":"4","key":"1469_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/aje\/kwx314","volume":"187","author":"H Poustchi","year":"2018","unstructured":"Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647\u201355.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1469_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s12889-018-5364-2","volume":"18","author":"A Khaledifar","year":"2018","unstructured":"Khaledifar A, Hashemzadeh M, Solati K, Poustchi H, Bollati V, Ahmadi A, et al. The protocol of a population-based prospective cohort study in southwest of Iran to analyze common non-communicable diseases: Shahrekord cohort study. BMC Public Health. 2018;18(1):660.","journal-title":"BMC Public Health"},{"issue":"2","key":"1469_CR19","first-page":"22","volume":"11","author":"H Ghobadi","year":"2012","unstructured":"Ghobadi H, Ahari SS, Kameli A, Lari SM. The relationship between COPD assessment test (CAT) scores and severity of airflow obstruction in stable COPD patients. Tanaffos. 2012;11(2):22\u20136.","journal-title":"Tanaffos"},{"issue":"10","key":"1469_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1164\/rccm.201207-1299OC","volume":"186","author":"P Lange","year":"2012","unstructured":"Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"1469_CR21","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41598-020-79707-y","volume":"11","author":"FZ Kiani","year":"2021","unstructured":"Kiani FZ, Ahmadi A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. Sci Rep. 2021;11:1548.","journal-title":"Sci Rep."},{"issue":"5","key":"1469_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","volume":"195","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1469_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.rmed.2011.01.008","volume":"105","author":"FAM Hoesein","year":"2011","unstructured":"Hoesein FAM, Zanen P, Lammers J-WJ. Lower limit of normal or FEV1\/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011;105(6):907\u201315.","journal-title":"Respir Med."},{"issue":"5","key":"1469_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1183\/09031936.02.00023202","volume":"20","author":"J Hardie","year":"2002","unstructured":"Hardie J, Buist AS, Vollmer W, Ellingsen I, Bakke P, M\u00f8rkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117\u201322.","journal-title":"Eur Respir J"},{"issue":"2","key":"1469_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1378\/chest.06-1349","volume":"131","author":"JE Hansen","year":"2007","unstructured":"Hansen JE, Sun X-G, Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1\/FVC ratio below the fifth percentile, not < 70%. Chest. 2007;131(2):349\u201355.","journal-title":"Chest"},{"issue":"6","key":"1469_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23(6):932\u201346.","journal-title":"Eur Respir J"},{"issue":"2","key":"1469_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1183\/09031936.00086313","volume":"43","author":"PH Quanjer","year":"2013","unstructured":"Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J. 2013;43(2):505\u201312.","journal-title":"Eur Respir J"},{"issue":"8","key":"1469_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1164\/rccm.201206-0996OC","volume":"186","author":"C Llor","year":"2012","unstructured":"Llor C, Moragas A, Hern\u00e1ndez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1469_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/15412555.2012.665520","volume":"11","author":"J Bourbeau","year":"2014","unstructured":"Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR, Coxson HO, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. COPD. 2014;11(2):125\u201332.","journal-title":"COPD"},{"issue":"1","key":"1469_CR30","first-page":"23","volume":"46","author":"P Adab","year":"2016","unstructured":"Adab P, Fitzmaurice D, Dickens A, Ayres J, Buni H, Cooper B, et al. Cohort profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) cohort study. Int J Epidemiol. 2016;46(1):23\u201323.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1469_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/COPD.S49621","volume":"9","author":"MC Smith","year":"2014","unstructured":"Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9(1):871\u201388.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1469_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.resinv.2016.07.001","volume":"54","author":"A Corlateanu","year":"2016","unstructured":"Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54(6):387\u201396.","journal-title":"Respir Investig"},{"issue":"5","key":"1469_CR33","doi-asserted-by":"publisher","first-page":"e0194819","DOI":"10.1371\/journal.pone.0194819","volume":"13","author":"YF Gebreyes","year":"2018","unstructured":"Gebreyes YF, Goshu DY, Geletew TK, Argefa TG, Zemedu TG, Lemu KA, et al. prevalence of high bloodpressure, hyperglycemia, dyslipidemia, metabolic syndrome and their determinants in Ethiopia: evidences from the National NCDs STEPS Survey, 2015. PLoS ONE. 2018;13(5):e0194819.","journal-title":"PLoS ONE"},{"issue":"19","key":"1469_CR34","doi-asserted-by":"publisher","first-page":"e6836","DOI":"10.1097\/MD.0000000000006836","volume":"96","author":"H-L Yin","year":"2017","unstructured":"Yin H-L, Yin S-Q, Lin Q-Y, Xu Y, Xu H-W, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine. 2017;96(19):e6836.","journal-title":"Medicine"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-021-01469-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T01:28:26Z","timestamp":1619746106000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01469-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-152306\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"21 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the observance of the Declaration of Helsinki and the National Ethical Guidelines in Biomedical Research in Iran. As well, the study protocol was approved by the Ethics Committee of the SKUMS (IR.SKUMS.REC 1394.286 and IR. SKUMS.1396.110) at regional and national scales. All participants provided signed and fingerprinted informed written consent. For illiterate participants, the informed consent form was read. After consent, the consent form was taken with a fingerprint. The consent of the participant was also signed and confirmed by his first-degree family member or legally authorized representatives. We provided signed and fingerprinted informed written consent according to the guidelines enforced by the Ethics Committee of the SKUMS. The participants can withdraw from the study whenever they wish. Data are stored in a codified confidential database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}